Alembic Pharmaceuticals Limited — Updates, 05-08-2025: Press Release

Alembic Pharmaceuticals reported strong Q1 FY26 consolidated financial results. Revenue surged 10% to Rs. 1,711 Cr, with Profit After Tax (PAT) jumping 15% to Rs. 154 Cr. EBITDA grew 20% to Rs. 288 Cr. Growth was broad-based: RoW markets soared 21%, US Generics climbed 13% despite pricing pressures (volume-led), and India Branded business rose 5%. The company launched 3 new products in India and 4 in the US, securing 6 new ANDA approvals. Management expects improved operating leverage from new facility utilization and cost optimization.